Figure 10:

Effect of Mfsd2a overexpression on Keap-1/Nrf-2 interaction and effect of Nrf-2 and HO-1 inhibition on neurologic outcome at 24 hours following SBI

A) Representative Western blot images and quantitative analysis demonstrating the effect of Mfsd2a CRISPR Act on Keap-1 co-immunoprecipitation with Nrf2 revealed that overexpression of Mfsd2a significantly increased Nrf-2 dissociation from Keap-1 following SBI (n= 4/group).

Neurologic outcome assessment with mGarcia score (B), beam balance score (C) and percentage of foot faults (D) at 24 hours following SBI showed that the beneficial effect of Mfsd2a CRISPR Act on neurologic functions was significantly diminished with the administration of Brusatol and ZnPP (n= 6/group).

Data are expressed as mean ± SD. ANOVA, Tukey. **p<0.001 compared to Sham, *p<0.05 compared to Sham, #p<0.05 compared to SBI, &&p<0.001 compared to SBI + Scramble CRISPR Act, &p<0.05 compared to SBI + Scramble CRISPR Act, $$p<0.001 compared to SBI + Mfsd2a CRISPR Act (2 μg), $p<0.05 compared to SBI + Mfsd2a CRISPR Act (2 μg).

SBI: Surgical brain injury